At Macrogen, we use a variety of highly sensitive NGS tests to analyze genetic mutations associated with cancer, to help with the prevention, early detection and treatment of cancer.
As cancer is the leading cause of death in Korea, Macrogen offers services to help ward off and address this risk as much as possible. An NGS targeted sequencing panel that is highly customized to each individual is used to screen for, detect and monitor cancers of various types, from those hereditary in nature, to those in their early stages, to those that have progressed or metastasized.
The Axen™ Cancer Panel is a pan-cancer panel using capture hybridization technology. With better coverage than conventional methods, the Axen™ Cancer Panel is able to effectively detect a wide range of aberration types in exons of genes associated with cancer, including not only SNV and InDel, but also fusion genes, CNV, TMB and MSI. Depending on the desired range of analysis, you can choose among three types of cancer panels, consisting of as few as 88 genes or as many as 559 genes. Both liquid biopsy and tumor biopsy are available for the panels.
Hereditary Cancer Panel
The Axen™ Test for Hereditary Cancer that uses blood samples to screen for some of the most common inherited cancers has been cited in many papers for its unique design that allows for genetic mutations to be effectively checked for, paving the way for early detection of specific cancer syndromes. Specifically, the Axen Test applies a next-generation genome sequencing technique to analyze all at once 69 genes closely linked with hereditary cancers, of which breast cancer and colorectal cancer, are the most widely known.
BRCA 1/2 Cancer Panel
Analysis can be done on the full range of the BRCA1/2 gene, well known to its association with an elevated risk for hereditary breast and ovarian cancers.
Alternatively, 53 relevant genes, including the BRCA1/2 can be analyzed. For those with a family history of breast cancer or ovarian cancer, selective screening can be conducted to forecast the risk of incidence caused by gene mutations. The thorough and precise analysis and testing conducted by Macrogen on gene mutations in patients diagnosed with cancer also helps in designing the best treatment program tailored to the individual’s needs.
Gastric Cancer Panel
The Axen™ Gastric Cancer Panel was designed to analyze various types of stomach cancer by selectively focusing on genes that are more likely to show mutations in patients of stomach cancer. Particular emphasis is placed on genes associated with specific types of stomach cancer that are most common in Asians or Koreans; Somatic analysis is carried out to detect the intestinal type stomach cancer, which accounts for the majority of stomach cancers. CDH1, ARID1A and RHOA, found to be clinically significant in diffuse-type stomach cancers, are also analyzed as part of the panel, offering broad coverage in detecting stomach cancers including those that are hereditary in nature.